Which companies are Gujarat Themis Biosyn's closest peers?

The cockpit's peer set: Newland Pharmaceutical (301277.SZ), Capricor Therapeutics (CAPR), Handa Pharmaceuticals (6620.TWO), Hefei Lifeon Pharmaceutical (003020.SZ), Egetis Therapeutics (EGTX.ST), Shandong Wohua Pharmaceutical (002107.SZ), Morepen Laboratories (MOREPENLAB.NS), Boryung (003850.KS).

Is Gujarat Themis Biosyn expensive compared with its peers?

On ev / sales it trades at 28.5× against a peer median of 3.7×, 2nd most expensive of 18 in its peer set.

How has Gujarat Themis Biosyn stock performed?

Over six months to 6 Nov 2026 the shares returned -4.8% against -18.9% for the median peer; over one year -18.6%.

← CockpitCompetitor Analysis › GUJTHEM.NS Gujarat Themis Biosyn LtdOpen in the cockpit ↗

Gujarat Themis Biosyn LtdGUJTHEM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Momentum strong 62

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$524M

US dollars, full cap

Free float

39%

of shares outstanding

$/day

$1.01M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-2.4 pp

WACC 20.0%

Hurdle

n/a

no reverse DCF

Close · INR₹380.20

1D-2.0%

1W+4.7%

1M+0.2%

3M+5.1%

6M-4.8%

YTD-13.9%

1Y-18.6%

ATR %5.5%

Beta1.42

52w lowhigh19.4% off high

What Gujarat Themis Biosyn does

Employees: 379

Gujarat Themis Biosyn at a glance

Size Gujarat Themis Biosyn (GUJTHEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $524M, the 821st largest of 1,058 India companies the cockpit tracks. Shares closed at ₹380.20 on 6 Nov 2026.

Performance Over six months the shares fell 4.8%, against -18.9% for the median peer and 0.0% for the India market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median +9.4%); the operating margin is 38.9% (peer median 6.8%).

Valuation It trades at 28.5× enterprise value to sales against a peer median of 3.7× (2nd most expensive of 18).

Capital Return on invested capital runs 2.4 points below its cost of capital (20.0% WACC).

Relative performance

Six months, rebased to 100: Gujarat Themis Biosyn against the median of its 20 peers (local-currency closes).

Gujarat Themis Biosyn financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹1.74B	₹1.66B	₹1.51B	₹1.70B	₹1.48B
Revenue growth	—	+10%	-11%	+14%	—
Gross profit	₹822M	₹769M	₹737M	₹863M	₹797M
EBITDA	₹824M	₹772M	₹709M	₹788M	₹748M
Net income	₹487M	₹467M	₹488M	₹592M	₹580M
Free cash flow	n/a	-₹1.28B	-₹220M	-₹94.3M	₹99.2M
Capital expenditure	n/a	₹1.73B	₹1.16B	₹746M	₹237M
Total debt	n/a	₹1.62B	₹305M	₹27.7M	₹4.19M

Quarterly statements and history in the cockpit →

Gujarat Themis Biosyn competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Gujarat Themis Biosyn is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gujarat Themis Biosyn is the large dot.

Gujarat Themis Biosyn competitors and peer comparison

How Gujarat Themis Biosyn compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gujarat Themis Biosyn against its 20 peers (data as of 6 Nov 2026)
Measure	GUJTHEM.NS	Peer median	Rank in peer set
1-month return	+0.2%	-9.3%	6th highest of 21
6-month return	-4.8%	-18.9%	7th highest of 21
Distance from 52-week high	-19.4%	-37.2%	3rd highest of 21
Revenue growth (TTM)	+17.5%	+9.4%	5th highest of 20
Operating margin	38.9%	6.8%	2nd highest of 18
EV / Sales	28.5×	3.7×	2nd most expensive of 18
ROIC minus cost of capital	-2.4 pp	-3.1 pp	9th highest of 19
EV / EBITDA	60.0×	18.3×	most expensive of 4
Net debt / EBITDA	1.9×	0.2×	most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Gujarat Themis Biosyn GUJTHEM.NS	India	$524M	-5%	+18%	39%	28.5×	n/a	n/a
Newland Pharmaceutical 301277.SZ	China	$523M	-22%	+9%	11%	3.9×	10.2%	+9.1%
Capricor Therapeutics CAPR	United States	$523M	-73%	-100%	n/a	n/a	n/a	n/a
Handa Pharmaceuticals 6620.TWO	Taiwan	$525M	+43%	+68%	37%	11.3×	12.9%	+126.7%
Hefei Lifeon Pharmaceutical 003020.SZ	China	$520M	-20%	-1%	10%	2.1×	n/a	n/a
Egetis Therapeutics EGTX.ST	Sweden	$528M	+67%	+39%	-604%	73.5×	n/a	n/a
Shandong Wohua Pharmaceutical 002107.SZ	China	$519M	-18%	-4%	18%	4.0×	6.7%	-4.1%
Morepen Laboratories MOREPENLAB.NS	India	$529M	+110%	+30%	11%	2.2×	n/a	n/a
Boryung 003850.KS	South Korea	$531M	-14%	+6%	6%	0.7×	-8.9%	+12.6%
Henan Taloph Pharmaceutical Stock 600222.SS	China	$533M	-5%	-5%	7%	2.7×	17.7%	+4.4%
Zhejiang Yatai Pharmaceutical 002370.SZ	China	$514M	-32%	-4%	-11%	9.8×	n/a	n/a
ChengDa PharmaCeuticals 301201.SZ	China	$535M	-43%	+27%	-9%	5.7×	n/a	n/a
Xizang Weixinkang Pharmaceutical 603676.SS	China	$538M	-22%	-8%	16%	2.4×	-5.2%	+9.6%
Indaptus Therapeutics INDP	United States	$510M	+64%	n/a	n/a	n/a	n/a	n/a
Zeria Pharmaceutical 4559.T	Japan	$540M	-6%	+12%	15%	1.0×	-12.5%	+11.1%
Gyre Therapeutics GYRE	United States	$505M	-36%	+17%	-11%	4.1×	n/a	n/a
Shanghai Xiao Fang Pharmaceutical 603207.SS	China	$544M	-14%	+10%	39%	5.3×	-3.9%	+7.6%
REGENXBIO RGNX	United States	$503M	-28%	+12%	-94%	3.7×	n/a	n/a
Jiangsu Lianhuan Pharmaceutical 600513.SS	China	$546M	-44%	+14%	0%	1.9×	n/a	n/a
Entera Bio ENTX	United States	$546M	+142%	-100%	n/a	n/a	n/a	n/a
Xiangxue Pharmaceutical 300147.SZ	China	$502M	-49%	+3%	-39%	3.3×	47.1%	-12.3%

Questions

Which companies are Gujarat Themis Biosyn's closest peers?: The cockpit's peer set: Newland Pharmaceutical (301277.SZ), Capricor Therapeutics (CAPR), Handa Pharmaceuticals (6620.TWO), Hefei Lifeon Pharmaceutical (003020.SZ), Egetis Therapeutics (EGTX.ST), Shandong Wohua Pharmaceutical (002107.SZ), Morepen Laboratories (MOREPENLAB.NS), Boryung (003850.KS).
Is Gujarat Themis Biosyn expensive compared with its peers?: On ev / sales it trades at 28.5× against a peer median of 3.7×, 2nd most expensive of 18 in its peer set.
How has Gujarat Themis Biosyn stock performed?: Over six months to 6 Nov 2026 the shares returned -4.8% against -18.9% for the median peer; over one year -18.6%.